SAF312
Total Payments
$166,690
Transactions
10
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $18,424 | 4 | 0 |
| 2017 | $148,266 | 6 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $166,659 | 9 | 100.0% |
| Food and Beverage | $30.68 | 1 | 0.0% |
Payments by Type
Research
$166,659
9 transactions
General
$30.68
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FIRST IN HUMAN DOSE ESCALATION | Novartis Pharmaceuticals Corporation | $115,845 | 0 |
| A RANDOMIZED VEHICLE CONTROLLED SUBJECT AND INVESTIGATOR MASKED PROOF OF CONCEPT STUDY TO EVALUATE THE USE OF TOPICAL OCULAR SAF312 IN THE TREATMENT OF POSTOPERATIVE OCULAR PAIN IN PATIENTS UNDERGOING PHOTOREFRACTIVE KERATECTOMY PRK SURGERY | Novartis Pharmaceuticals Corporation | $50,814 | 0 |
Top Doctors Receiving Payments for SAF312
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chevy Chase, MD | $166,659 | 9 |
| , M.D | Endocrinology, Diabetes & Metabolism | Jacksonville, FL | $30.68 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $166,690
Product Information
- Type Drug
- Total Payments $166,690
- Total Doctors 1
- Transactions 10
About SAF312
SAF312 is a drug associated with $166,690 in payments to 1 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $18,424 was paid across 4 transactions to 0 doctors.
The most common payment nature for SAF312 is "Unspecified" ($166,659, 100.0% of total).
SAF312 is associated with 2 research studies, including "FIRST IN HUMAN DOSE ESCALATION" ($115,845).